journal article Jun 01, 2012

Structure–activity relationship of a series of non peptidic RGD integrin antagonists targeting α5β1: Part 1

Bénédicte Delouvrié Katherine Al-Kadhimi Jean-Claude Arnould Simon T. Barry

Darren A.E. Cross Myriam Didelot Paul R. Gavine Hervé Germain Craig S. Harris Adina M. Hughes David A. Jude Jane Kendrew Christine Lambert-van der Brempt Jean-Jacques Lohmann Morgan Ménard Andrew A. Mortlock Martin Pass Claire Rooney Michel Vautier Jennifer L. Vincent Nicolas Warin

Bioorganic & Medicinal Chemistry Letters Vol. 22 No. 12 pp. 4111-4116 · Elsevier BV

View at Publisher Save 10.1016/j.bmcl.2012.04.063

Topics

No keywords indexed for this article. Browse by subject →

References

32

[1]

Yang Development (1993) 10.1242/dev.119.4.1093

[2]

Kim Am. J. Pathol. (2000) 10.1016/s0002-9440(10)65005-5

[3]

Adachi Clin. Cancer Res. (2000)

[4]

Bhaskar Invest. New Drugs (2008) 10.1007/s10637-007-9078-z

[5]

Umeda Mol. Pharmacol. (2006)

[6]

Chuntharapai, A.; Plowman, G.; Tessier-Lavigne, M.; Wu, Y.; Ye, W. WO2008/060645, 2008.

[7]

Jadhav, P. K.; Smallheer, J. M. WO1997/033887, 1997.

[8]

Smallheer Bioorg. Med. Chem. Lett. (2004) 10.1016/j.bmcl.2003.10.057

[9]

Marinelli J. Med. Chem. (2005) 10.1021/jm040224i

[10]

Stragies J. Med. Chem. (2007) 10.1021/jm070002v

[11]

Zischinsky Bioorg. Med. Chem. Lett. (2010) 10.1016/j.bmcl.2009.11.030

[12]

Zischinsky Bioorg. Med. Chem. Lett. (2010) 10.1016/j.bmcl.2009.10.073

[13]

Heckmann Angew. Chem., Int. Ed. (2007) 10.1002/anie.200700008

[14]

Heckmann ChemBioChem (2008) 10.1002/cbic.200800045

[15]

Tamaskar Drugs Future (2010) 10.1358/dof.2010.35.1.1450650

[16]

Kuwada Curr. Opin. Mol. Ther. (2007)

[17]

Khalili Mol. Cancer Ther. (2006) 10.1158/1535-7163.mct-06-0100

[18]

Cianfrocca Br. J. Cancer (2006) 10.1038/sj.bjc.6603171

[19]

Xiong Science (2002) 10.1126/science.1069040

[20]

Gottschalk Angew. Chem., Int. Ed. (2002) 10.1002/1521-3773(20021018)41:20<3767::aid-anie3767>3.0.co;2-t

[21]

Tagaki Embo J. (2003) 10.1093/emboj/cdg445

[22]

A hierarchical approach to all‐atom protein loop prediction

Matthew P. Jacobson, David L. Pincus, Chaya S. Rapp et al.

Proteins: Structure, Function, and Bioinformatics 2004 10.1002/prot.10613

[23]

On the Role of the Crystal Environment in Determining Protein Side-chain Conformations

Matthew P. Jacobson, Richard A. Friesner, Zhexin Xiang et al.

Journal of Molecular Biology 2002 10.1016/s0022-2836(02)00470-9

[24]

Davenport Drug Discovery Today (2007) 10.1016/j.drudis.2007.05.001

[25]

Cacciari Curr. Med. Chem. (2005) 10.2174/0929867053363522

[26]

Arnould, J.-C.; Delouvrié, B.; Ducray, R.; Lambert-Van Der Brempt, C. M. P. WO2007/141473, 2007.

[27]

Leonard Bioorg. Med. Chem. Lett. (2005) 10.1016/j.bmcl.2005.01.028

[28]

Urbahns Bioorg. Med. Chem. Lett. (2002) 10.1016/s0960-894x(01)00717-x

[29]

Urbahns Bioorg. Med. Chem. Lett. (2003)

[30]

Scarborough J. Med. Chem. (2000) 10.1021/jm000022w

[31]

Structural basis for allostery in integrins and binding to fibrinogen-mimetic therapeutics

Tsan Xiao, Junichi Takagi, Barry S. Coller et al.

Nature 2004 10.1038/nature02976

[32]

Springer Cell Biol. (2008) 10.1083/jcb.200801146

Metrics

9

Citations

32

References

Details

Published: Jun 01, 2012
Vol/Issue: 22(12)
Pages: 4111-4116
License: View

Authors

Bénédicte Delouvrié

Katherine Al-Kadhimi

Jean-Claude Arnould

Darren A.E. Cross

11Bioscience, Early Oncology TDE, AstraZeneca, Cambridge, United Kingdom.

Craig S. Harris

Adina M. Hughes

Christine Lambert-van der Brempt

Centre de Recherches, AstraZeneca, Z. I. La Pompelle, Chemin de Vrilly, BP 1050, 51689 Reims Cedex 2, France

Jean-Jacques Lohmann

Centre de Recherches, AstraZeneca, Z. I. La Pompelle, Chemin de Vrilly, BP 1050, 51689 Reims Cedex 2, France

Andrew A. Mortlock

AstraZeneca R&D Alderley Park, Cheshire, SK10 4TG, United Kingdom

AstraZeneca Oncology Innovative Medicines, Macclesfield, United Kingdom

Centre de Recherches, AstraZeneca, Z. I. La Pompelle, Chemin de Vrilly, BP 1050, 51689 Reims Cedex 2, France

Jennifer L. Vincent

Centre de Recherches, AstraZeneca, Z. I. La Pompelle, Chemin de Vrilly, BP 1050, 51689 Reims Cedex 2, France

Cite This Article

Bénédicte Delouvrié, Katherine Al-Kadhimi, Jean-Claude Arnould, et al. (2012). Structure–activity relationship of a series of non peptidic RGD integrin antagonists targeting α5β1: Part 1. Bioorganic & Medicinal Chemistry Letters, 22(12), 4111-4116. https://doi.org/10.1016/j.bmcl.2012.04.063

Related

You May Also Like

Physiochemical drug properties associated with in vivo toxicological outcomes

Jason D. Hughes, Julian Blagg · 2008

889 citations

The SARS-CoV-2 main protease as drug target

Sven Ullrich, Christoph Nitsche · 2020

684 citations

Carbonic anhydrase inhibitors

Claudiu T. Supuran · 2010

597 citations

Antioxidant activity of water-soluble chitosan derivatives

Wenming Xie, Peixin Xu · 2001

526 citations

Proteolysis targeting chimeras (PROTACs) in ‘beyond rule-of-five’ chemical space: Recent progress and future challenges

Scott D. Edmondson, Bin Yang · 2019

364 citations